US 12,226,382 B2
Methods for treating microglial dysfunction
Marco Colonna, St. Louis, MO (US); and Tyler Ulland, St. Louis, MO (US)
Assigned to Washington University, St. Louis, MO (US)
Filed by Washington University, St. Louis, MO (US)
Filed on Aug. 5, 2021, as Appl. No. 17/395,357.
Application 17/395,357 is a continuation of application No. 16/030,793, filed on Jul. 9, 2018, abandoned.
Claims priority of provisional application 62/529,753, filed on Jul. 7, 2017.
Prior Publication US 2021/0393563 A1, Dec. 23, 2021
Int. Cl. A61K 31/195 (2006.01); A61P 25/28 (2006.01); C12Q 1/6827 (2018.01); C12Q 1/6883 (2018.01)
CPC A61K 31/195 (2013.01) [A61P 25/28 (2018.01); C12Q 1/6827 (2013.01); C12Q 1/6883 (2013.01); C12Q 2600/156 (2013.01)] 9 Claims
 
1. A method for treating a microglial dysfunction-associated neurodegenerative disease in a subject in need thereof, the method comprising:
administering to the subject a therapeutically effective amount of a composition comprising a microglial rescuing agent, wherein the microglial rescuing agent is cyclocreatine or a pharmaceutically acceptable salt thereof;
wherein the microglial dysfunction-associated neurodegenerative disease is a neurodegenerative disease characterized by SNPs or mutations effecting a TREM2 variant or an ApoE variant, resulting in decreased microglial activity; and
wherein the microglial dysfunction-associated neurodegenerative disease is Alzheimer's disease.